ADC Therapeutics SA Common Shares (ADCT)

About ADCT

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or ref…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

188

Website

adctherapeutics.com/

Fundamentals

1-day range

$1.02$1.09

Market cap

$143.73M

P/E (trailing)

—

P/E (forward)

-0.70

EPS (trailing)

$-1.12

Dividend yield

—

Beta

1.87

Avg. volume

1.87M

Forecasts

3 analyst ratings

ADC Therapeutics SA Common Shares Competitors

Chosen by industry and closest market cap.

• ADCT

  ADC Therapeutics SA Common Shares

  $1.15

  ▲ 2.68%
  Market cap $143.73MP/E —
  $0.7796$4.98
• CNTN

  Canton Strategic Holdings Inc. Common Stock

  $2.23

  ▼ 5.32%
  Market cap $143.45MP/E —
  $1.75$7.25
• KZIA

  Kazia Therapeutics Limited American Depositary Shares

  $13.59

  ▼ 19.59%
  Market cap $140.89MP/E —
  $4.86$17.4
• MIST

  Milestone Pharmaceuticals Inc. Common Shares

  $1.17

  ▼ 2.10%
  Market cap $146.91MP/E —
  $1$3.06
• CNTB

  Connect Biopharma Holdings Limited Ordinary Shares

  $2.22

  ▼ 2.63%
  Market cap $137.89MP/E —
  $1.23$3.82
• VTVT

  vTv Therapeutics Inc. Class A Common Stock

  $32.17

  ▼ 1.92%
  Market cap $136.33MP/E 55.59
  $15.79$44
• HURA

  TuHURA Biosciences Inc. Common Stock

  $2.11

  ▼ 1.17%
  Market cap $134.69MP/E —
  $0.41$3.43

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• ADC Therapeutics (ADCT) Price Target Increased by 43.18% to 2.68
  Fintel · 8/28/2026
• Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
  Benzinga · 8/17/2026
• ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• ADC Therapeutics Q2 2026 Earnings Call Transcript
  Benzinga · 8/13/2026
• ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate
  Benzinga · 8/13/2026

• Mohamed Zaki · June 30, 2026 · Grant

  213.9K
• Ameet Mallik · June 30, 2026 · Grant

  675.0K
• Jose Carmona · June 30, 2026 · Grant

  203.7K
• Peter J. Graham · June 30, 2026 · Grant

  221.1K
• Viviane Monges · June 3, 2026 · Tax Withholding

  2.6K @ $3.08
• Peter Hug · June 3, 2026 · Tax Withholding

  2.2K @ $3.08
• Robert Azelby · June 3, 2026 · Tax Withholding

  12.6K @ $3.08
• Jean-Pierre Bizzari · June 3, 2026 · Tax Withholding

  12.6K @ $3.08
• Victor Sandor · June 3, 2026 · Tax Withholding

  12.6K @ $3.08
• Ron Squarer · June 3, 2026 · Tax Withholding

  15.2K @ $3.08
• Timothy Coughlin · June 3, 2026 · Tax Withholding

  12.6K @ $3.08
• Viviane Monges · June 1, 2026 · Grant

  45.0K
• Peter Hug · June 1, 2026 · Grant

  45.0K
• Robert Azelby · June 1, 2026 · Grant

  45.0K
• Jean-Pierre Bizzari · June 1, 2026 · Grant

  45.0K